Lord Abbett Health Care R4 (LHCSX)
| Fund Assets | 8.67M |
| Expense Ratio | 1.03% |
| Min. Investment | $0.00 |
| Turnover | 91.00% |
| Dividend (ttm) | 0.04 |
| Dividend Yield | 0.15% |
| Dividend Growth | -41.46% |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 2, 2025 |
| Previous Close | 24.30 |
| YTD Return | 6.80% |
| 1-Year Return | 32.98% |
| 5-Year Return | 24.75% |
| 52-Week Low | 18.01 |
| 52-Week High | 24.30 |
| Beta (5Y) | n/a |
| Holdings | 60 |
| Inception Date | Jul 31, 2019 |
About LHCSX
Lord Abbett Health Care Fund Class R4 is an actively managed mutual fund that seeks to achieve long-term capital growth by investing primarily in the stocks of companies within the health care sector. The fund targets a broad range of firms involved in health care, including health care equipment, pharmaceuticals, biotechnology, and related industries, both in the United States and internationally. Its investment strategy focuses on identifying opportunities across various health care sub-sectors, aiming to capture growth trends and innovation in one of the world’s most dynamic industries. The fund’s holdings may include established market leaders as well as emerging companies developing new medical treatments and technologies. Lord Abbett Health Care Fund Class R4 is positioned as a sector-specific fund, offering investors targeted exposure to the health care industry, which plays a critical role in the global economy due to ongoing demographic shifts, advancements in medical research, and changing health care needs. It is particularly relevant for investors seeking to diversify their portfolios with a focus on industry trends and innovations shaping the future of health care. The fund is characterized by a net expense ratio that is higher than average compared to its peers, reflecting the active management approach and specialized sector focus.
Performance
LHCSX had a total return of 32.98% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.14%.
Top 10 Holdings
38.34% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.06% |
| AstraZeneca PLC | AZN | 4.82% |
| Gilead Sciences, Inc. | GILD | 4.33% |
| Johnson & Johnson | JNJ | 3.25% |
| Nektar Therapeutics | NKTR | 3.23% |
| Natera, Inc. | NTRA | 2.97% |
| Tarsus Pharmaceuticals, Inc. | TARS | 2.88% |
| Guardant Health, Inc. | GH | 2.68% |
| argenx SE | ARGX | 2.61% |
| Novartis AG | NOVN | 2.52% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 2, 2025 | $0.036 | Dec 2, 2025 |
| Nov 26, 2024 | $0.0615 | Nov 26, 2024 |
| Nov 23, 2021 | $1.4724 | Nov 23, 2021 |
| Nov 24, 2020 | $2.3119 | Nov 24, 2020 |